Nishank Jain

Associate Professor

University of Arkansas for Medical Sciences

faculty

Internal Med, College of Medicine

17 h-index 61 pubs 1,190 cited

Research Areas

Platelet Disorders and Treatments Dialysis and Renal Disease Management Immune Response and Inflammation Pharmacological Effects and Toxicity Studies Cardiovascular Function and Risk Factors Health Sciences Research and Education Innovations in Medical Education

Links

ORCID Research Group UAMS TRI Profile

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

Nishank Jain, MD, MPH, is an Associate Professor in the Department of Medicine at the University of Arkansas for Medical Sciences. His research investigates the role of platelets in the pathophysiology of chronic kidney disease (CKD) and examines the use of antiplatelet agents in individuals with kidney diseases. Dr. Jain has received funding for his work from the American Heart Association (AHA) and the American Society of Nephrology through various career development and fellowship grants.

His scholarly output includes publications on topics such as the role of platelets in CKD, new therapies for CKD patients, and the impact of antiplatelet agents like ticagrelor and clopidogrel in CKD populations. He has also published on renal biomarkers in heart failure and the comparative effectiveness and safety of P2Y12 inhibitors in patients undergoing chronic dialysis. Dr. Jain's research network includes collaborators such as Jerry Ware, Jawahar L. Mehta, Adam Corken, and Otis M. Davis, all from the University of Arkansas for Medical Sciences.

In addition to his research endeavors, Dr. Jain is committed to medical education. He focuses on training and engaging medical students in academic medicine, and has received teaching awards for his work. He has facilitated opportunities for medical students to present their research at national meetings and achieve Honors in Research upon graduation.

Research Overview

Nishank Jain, MD, MPH, is a nephrologist and an Associate Professor in the Department of Medicine at University of Arkansas for Medical Sciences, Little Rock, AR. He completed his clinical and research fellowship at UT Southwestern Medical Center, Dallas, TX, before joining as a faculty member. His research interest is in the role of platelets in CKD pathophysiology and use of antiplatelet agents in patients with kidney diseases. He has been funded by post-doctoral fellowship grant from the American Heart Association (AHA), institutional KL2 grant and career development grants from the American Society of Nephrology and the AHA. Dr. Jain is passionate about education and is driven by training and engaging medical students for a career in academic medicine. He has also helped medical students receive Honors in Research upon graduation. Dr. Jain has received medical student teaching awards. He has also engaged in SSCI activities by sending medical students to present original research work at the Annual Meetings.

Metrics

h-index: 17
Publications: 61
Citations: 1,190

Selected Publications

Fungal DNA in Circulation (2025) DOI
AKI in Patients Receiving Chimeric Antigen Receptor T Cells: Risk Factors and Characteristics (2025) DOI
Hypophosphatemia as a Marker for Immune Effector Cell-Associated Neurotoxicity Syndrome in Chimeric Antigen Receptor T Cell Recipients (2025) DOI
Sepsis-Related Hospitalization and Mortality in Patients with CKD (2025) DOI
Left Atrial Appendage Occlusion vs Anticoagulants in Dialysis With Atrial Fibrillation (2025) DOI
Potent P2Y12 Receptor Inhibitors Reduce Risk for Hospitalization from Sepsis in Patients with CKD (2025) DOI
Higher Glycolysis in Circulating Leukocytes in Patients with CKD (2024) DOI
Platelets, inflammation, and purinergic receptors in chronic kidney disease (2024) DOI
P2Y12 Inhibitors Refill Gap Predicts Death in Medicare Beneficiaries on Chronic Dialysis (2024) DOI
EFFICACY AND OUTCOMES OF LEFT ATRIAL APPENDAGE OCCLUSION IN PATIENTS WITH ATRIAL FIBRILLATION AND ESRD (2024) DOI
Response to [Challenging the Restrictive Approach: Reconsidering SGLT-2 Inhibitor Use in CKD] (2024) DOI
Authors' Reply: Platelet Count, Platelet Volume and CKD (2024) DOI
Renal Biomarkers in Heart Failure (2024) DOI
Use of Antiplatelet Drugs Targeting Platelet P2Y12 Receptor Is Associated with Reduced Risk for Infectious Death in Veterans with CKD (2023) DOI
Depression and Other Psychological Issues in CKD (2023) DOI

Grants & Funding

Glycolysis in Leukocytes and Inflammation in Patients with CKD Dialysis Clinic, Inc. Principal Investigator
Platelet, Inflammation and Thrombosis in Chronic Kidney Disease NIH/NCATS Principle Investigator
Platelet-Leukocyte Axis in Patients with Chronic Kidney Disease Dialysis Clinic, Inc. Principal Investigator
Glycolysis in Leukocytes and Inflammation in Patients with CKD Dialysis Clinic, Inc. Principal Investigator
Platelet-Leukocyte Axis in Patients with Chronic Kidney Disease Dialysis Clinic, Inc. Principal Investigator
Platelet-Leukocyte Axis in Patients with Chronic Kidney Disease Dialysis Clinic, Inc. Principal Investigator
Effectiveness and safety of clopidogrel, prasugrel and ticagrelor in patients with end stage renal disease (ESCALATE) American Heart Association Principal Investigator
Platelet-Leukocyte Axis in Patients with Chronic Kidney Disease Dialysis Clinic, Inc. Principal Investigator